Basit öğe kaydını göster

dc.contributor.authorYounossi, Zobair M.
dc.contributor.authorGolabi, Pegah
dc.contributor.authorPaik, James
dc.contributor.authorOwrangi, Soroor
dc.contributor.authorYılmaz, Yusuf
dc.contributor.authorEl-Kassas, Mohamed
dc.contributor.authorAlswat, Khalid
dc.contributor.authorAlqahtani, Saleh A.
dc.date.accessioned2024-03-20T06:27:51Z
dc.date.available2024-03-20T06:27:51Z
dc.date.issued2024en_US
dc.identifier.citationYounossi, Z. M., Golabi, P., Paik, J., Owrangi, S., Yilmaz, Y., El-Kassas, M., Alswat, K., & Alqahtani, S. A. (2024). Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver international : official journal of the International Association for the Study of the Liver, 10.1111/liv.15852. Advance online publication. https://doi.org/10.1111/liv.15852en_US
dc.identifier.issn1478-3223
dc.identifier.urihttps://doi.org/10.1111/liv.15852
dc.identifier.urihttps://hdl.handle.net/11436/8833
dc.description.abstractBackground and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NAFLD/MASLD in the general population and among patients with T2D in the Middle East and North Africa (MENA) region. Methods: We searched PubMed and Embase for English-language articles published between 1990 and 2023 according to PRISMA. Each country's NAFLD/MASLD prevalence in the general population and in T2D patients was predicted by using a multivariable meta regression model. Input data were extracted from our systematic review, GBD and NCD Risk Factor Collaboration. Confidence intervals were constructed by using prediction intervals with the delta method. Results: Meta-analytic pooling estimated the prevalence of NAFLD/MASLD as 39.43% in the general population and 68.71% among T2D patients. NAFLD/MASLD prevalence has increased from 35.42% (2008–2016) to 46.20% (2017–2020). Using GBD-2019 dataset, it was predicted that there are 141.51 million cases of NAFLD/MASLD in the MENA region. The highest number of NAFLD/MASLD cases were expected in Egypt (25.71 million), followed by Türkiye (23.33 million) and Iran (19.85 million). Estimated NAFLD prevalence exceeded 40% in 10 of 21 countries with the top countries being Kuwait (45.37%), Egypt (45.0%), Qatar (44.4%), and Jordan (43.3%). Furthermore, it was predicted that there are 24.96 million cases of NAFLD/MASLD with T2D in the MENA region. Conclusions: In the MENA region, prevalence of NAFLD/MASLD is very high and growing, necessitating an urgent need for regional public policy to deal with this growing burden.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMASHen_US
dc.subjectMASLDen_US
dc.subjectMENAen_US
dc.subjectMiddle Easten_US
dc.subjectNAFLDen_US
dc.subjectNASHen_US
dc.subjectNorth Africaen_US
dc.subjectSteatotic liver diseaseen_US
dc.subjectT2Den_US
dc.titlePrevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africaen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorYılmaz, Yusuf
dc.identifier.doi10.1111/liv.15852en_US
dc.relation.journalLiver Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster